JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says

Pfizer was among the drugmakers most elevated by the COVID-19 pandemic, and, going forward, the pharma giant has no plans to give up on its current momentum.

Speaking this week at the J.P. Morgan Healthcare Conference in San Francisco, Pfizer CEO Albert Bourla, Ph.D., laid out scenarios (PDF) that could take the drugmaker to $84 billion—or $70 billion in a less ambitious case—in non-COVID revenues in 2030.